COMPASS Pathways Plc - American Depository Shares (CMPS)

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET.

EQNX::TICKER_START (NYSEJNJ),NASDAQ:CMPSNASDAQCMPS)(NASDAQ:MNMDNASDAQMNMD,(NASDAQ:ATAINASDAQ),(NYSE:ABBVABBV) EQNX::TICKER_END

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company’s New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. 

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression

EQNX::TICKER_START (NYSECYBN),NASDAQ:CMPSNASDAQCMPS)(NASDAQ:MNMDNASDAQMNMD,(NASDAQ:SEELNASDAQ),(NASDAQ:ATAIATAI) EQNX::TICKER_END

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an update on recent progress across its business.

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities. Mary-Rose Hughes, current Vice President of Finance at COMPASS, will assume the role of interim CFO effective today. COMPASS has begun a search to select a permanent Chief Financial Officer.

By Faith Ashmore, Benzinga

By Faith Ashmore, Benzinga

By Faith Ashmore, Benzinga

EQNX::TICKER_START (NYSEJNJ),NYSE:ABBVNYSEABBV)(NASDAQ:ATAINASDAQATAI,(NASDAQ:CMPSNASDAQ),(NASDAQ:MNMDMNMD) EQNX::TICKER_END

EQNX::TICKER_START (NYSECYBN),NEO:CYBN),NASDAQ:CMPSNASDAQCMPS)(NASDAQ:MNMDNASDAQMNMD,(NASDAQ:SEELNASDAQ),(OTCQX:NUMIF) EQNX::TICKER_END

By Rachael Green, Benzinga

Researchers from Compass Pathways PLC (NASDAQCMPS) have commenced the largest-ever phase 3 clinical trial investigating the effectiveness of psilocybin against depression. The mental health company first announced the phase 3 program in late 2022 during an online Capital Markets Day.

 LONDON, May 11, 2023 (GLOBE NEWSWIRE) --

COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved

COMPASS Pathways Plc (NASDAQCMPS) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 6.37% on the day to $10.53.

LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQATAI),NASDAQ:CMPSNASDAQCMPS)(NYSE:CYBNNYSECYBN,(NASDAQ:MNMDNASDAQ) EQNX::TICKER_END